Posted by: fuadelhibri on: April 2, 2012
Originally posted on Gazette.net Fuad El-Hibri has started a financial consulting business. He’s started telecommunications businesses. But his most challenging venture has been the Rockville biotech he helped launch 14 years ago. Still, El-Hibri — CEO and board chairman of Emergent BioSolutions — says the challenges are worth it, because the rewards are so great from protecting [...]
Posted by: fuadelhibri on: July 7, 2011
ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection. “Emergent [...]
Posted by: fuadelhibri on: April 13, 2011
2010 revenues of $286.2 million 2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability 2010 cash, investments and accounts receivable balance of $210.4 million 2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million Emergent BioSolutions Inc. (NYSE: EBS) announced [...]
Posted by: fuadelhibri on: January 5, 2011
ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed as part of Emergent’s [...]
Posted by: fuadelhibri on: November 13, 2010
The International Biomedical Research Alliance (IBRA) is a philanthropic organization that is dedicated to the support of the NIH-Oxford-Cambridge Scholars Program, which strives to establish the highest standards of excellence in training biomedical researchers, advance groundbreaking biomedical research, enrich the pool of leaders in the field, and eliminate barriers which frustrate the transfer of a [...]
Posted by: fuadelhibri on: October 23, 2010
ROCKVILLE, Md., Oct 13, 2010 — Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for third quarter 2010 on Thursday November 4, 2010, after market close. Company management will host a conference call at 5:00 pm Eastern on November 4, 2010 to discuss the financial results for the third quarter and [...]
Posted by: fuadelhibri on: September 20, 2010
ROCKVILLE, MD, September 17, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract, valued at up to $186.6 million, with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the development of a recombinant protective antigen (rPA) anthrax vaccine. This five [...]
Posted by: fuadelhibri on: September 10, 2010
New Contract Valued at up to $28.7 Million for Phase II Clinical Trial ROCKVILLE, Md., Sep 01, 2010 –Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH), [...]
Posted by: fuadelhibri on: August 3, 2010
Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of $40 to [...]
Posted by: fuadelhibri on: July 15, 2010
ROCKVILLE, Md., Jul 14, 2010 Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax(R) [...]
